Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Starpharma Holdings's Enterprise Value for the quarter that ended in Dec. 2025 was A$133.65 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Starpharma Holdings's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was A$-4.86 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Starpharma Holdings EV-to-EBIT Related Terms
Starpharma Holdings EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Starpharma Holdings's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:SPL vs VRTX, REGN, ALNY: EV-to-EBIT Comparison
For the Biotechnology subindustry, Starpharma Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Starpharma Holdings EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Starpharma Holdings's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Starpharma Holdings's EV-to-EBIT falls into.
Starpharma Holdings's current Enterprise Value is A$289.25 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Starpharma Holdings's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was A$-4.86 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Starpharma Holdings (ASX:SPL) has a EV-to-EBIT of -59.52 as of Jul. 18, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Starpharma Holdings and its competitors. According to the industry distribution chart, Starpharma Holdings ranks #999999 out of 372 companies in the Biotechnology industry.
Is Starpharma Holdings' EV-to-EBIT too high?
Starpharma Holdings' current EV-to-EBIT is -59.52. Based on the distribution chart, Starpharma Holdings ranks #999999 out of 372 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Starpharma Holdings has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Starpharma Holdings' EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Starpharma Holdings ranks #999999 out of 372 companies for EV-to-EBIT. This places Starpharma Holdings in the lower half of its industry. The industry median EV-to-EBIT is 13.35. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 13.35, based on 372 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Starpharma Holdings and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 13.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Starpharma Holdings's current EV-to-EBIT is -59.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Starpharma Holdings stock overvalued right now?
Based on GuruFocus' analysis, Starpharma Holdings (ASX:SPL) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.48, compared to a current price of A$0.71 — trading 47.9% above its estimated fair value. The current EV-to-EBIT is -59.52. Starpharma Holdings' overall GF Score™ is 49/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Starpharma Holdings (ASX:SPL), the current EV-to-EBIT is -59.52 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Starpharma Holdings (ASX:SPL) Overvalued in 2026?
Based on GuruFocus' analysis, Starpharma Holdings stock appears to be overvalued.
The current stock price of A$0.71 is trading 47.9% above its estimated GF Value™ of A$0.48.
GuruFocus considers Starpharma Holdings to be Significantly Overvalued.
Key valuation signals for ASX:SPL:
EV-to-EBIT: -59.52
GF Value™: A$0.48 vs. price of A$0.71 (47.9% above fair value)
No single metric tells the full story. See the ASX:SPL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Starpharma Holdings Ltd is an Australia-based company engaged in the research, development, and commercialization of dendrimer products for pharmaceutical, life science, and other applications. It focuses on the development of VivaGel for the management and prevention of bacterial vaginosis and as a condom coating, and VIRALEZE, an antiviral nasal spray.
49GF Score
Get the complete analysis for ASX:SPL
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:SPL has been successfully added to your 
